The US Department of Justice has taken a landmark step in drug policy by reclassifying certain marijuana products from Schedule I to Schedule III under the Controlled Substances Act. Acting Attorney General Todd Blanche signed the order on Thursday, aligning FDA-approved marijuana products and those under state medical marijuana licenses with less restrictive drugs like Tylenol with codeine.
This shift, directed by an executive order from President Donald Trump in December, aims to expand access to medical treatments and facilitate research into the drug’s safety and efficacy. Blanche emphasized the move as a fulfillment of Trump’s promise to enhance patient care and provide doctors with better data. The reclassification marks a historic pivot, though marijuana remains illegal at the federal level despite widespread state-level legalization for medical or recreational use.
Once published in the Federal Register, the rule change will take effect after a 30-day window. However, legal challenges are anticipated during this period, which could delay implementation for months or even years. The Drug Enforcement Agency has scheduled a hearing on the matter for late June to address potential objections.
RELATED: Cannabis to Be Reclassified Under Trump as Early as Wednesday
The policy change follows a broader push by the Trump administration to reform drug access. Just five days prior to the marijuana reclassification, Trump signed another executive order to increase access to psychedelic drugs for medical treatment, signaling a pattern of easing restrictions on controlled substances for therapeutic purposes.
While the reclassification does not alter the federal ban on marijuana, it reflects a growing divergence between state and federal policies. Most US states have already legalized marijuana in some form, with many operating legal dispensaries. The Schedule III status could pave the way for more robust clinical studies and potentially influence future legislative efforts.
Information for this story was found via the sources and companies mentioned. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
